Ritonavir and efavirenz significantly alter the metabolism of erlotinib - An observation in primary cultures of human hepatocytes that is relevant to HIV patients with cancer

Drug Metabolism and Disposition

Volumn 41, Issue 10, 2013, Pages 1843-1851

  Pillai, Venkateswaran C ^a   Venkataramanan, Raman ^a   Parise, Robert A ^b   Christner, Susan M ^b   Gramignoli, Roberto ^c   Strom, Stephen C ^c   Rudek, Michelle A ^d   Beumer, Jan H ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c KAROLINSKA INSTITUTE   (Sweden)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 INHIBITOR; DIMETHYL SULFOXIDE; EFAVIRENZ; ERLOTINIB; KETOCONAZOLE; RIFAMPICIN; RITONAVIR;

ADENOMA; ADULT; AGED; ANOXIA; AREA UNDER THE CURVE; ARTICLE; BILE DUCT CARCINOMA; CLINICAL ARTICLE; COLON CANCER; COLORECTAL CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG INHIBITION; DRUG METABOLISM; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LIQUID CHROMATOGRAPHY; LIVER CELL CULTURE; MALE; NODULAR HYPERPLASIA; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION;

14-ALPHA DEMETHYLASE INHIBITORS; ADULT; AGED; ANTI-HIV AGENTS; BENZOXAZINES; DRUG INTERACTIONS; FEMALE; HALF-LIFE; HEPATOCYTES; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; KETOCONAZOLE; MALE; MIDDLE AGED; NEOPLASMS; NUCLEIC ACID SYNTHESIS INHIBITORS; QUINAZOLINES; RIFAMPIN; RITONAVIR;

EID: 84884682224     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.113.052100     Document Type: Article

References (53)

1. Abbas R, Fettner S, Riek M, Bulsara S, Pantze M, Hamilton M, Frohna P, and Rakhit A (2003) A drug-drug interaction study to evaluate the effect of rifampicin on the pharmacokinetics of the EGF receptor tyrosine kinase inhibitor, erlotinib, in healthy subjects. Proc Am Soc Clin Oncol 22:548.
2. Backman JT, Granfors MT, and Neuvonen PJ (2006) Rifampicin is only a weak inducer of CYP1A2-mediated presystemic and systemic metabolism: studies with tizanidine and caffeine. Eur J Clin Pharmacol 62:451-461. (Pubitemid 43873717)
3. Baker SD and Hu S (2009) Pharmacokinetic considerations for new targeted therapies. Clin Pharmacol Ther 85:208-211.
4. Beumer JH (2013) Without therapeutic drug monitoring, there is no personalized cancer care. Clin Pharmacol Ther 93:228-230.
5. Boffito M, Acosta E, Burger D, Fletcher CV, Flexner C, Garaffo R, Gatti G, Kurowski M, Perno CF, and Peytavin G, et al. (2005) Therapeutic drug monitoring and drug-drug interactions involving antiretroviral drugs. Antivir Ther 10:469-477. (Pubitemid 41059193)
6. Borkar DS, Lacouture ME, and Basti S (2013) Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: a five-year review. Support Care Cancer 21: 1167-1174.
7. Chiba M, Ishii Y, and Sugiyama Y (2009) Prediction of hepatic clearance in human from in vitro data for successful drug development. AAPS J 11:262-276.
8. Deeken JF, Tjen ALA, Rudek MA, Okuliar C, Young M, Little RF, and Dezube BJ (2012) The rising challenge of non-AIDS-defining cancers in HIV-infected patients. Clin Infect Dis 55:1228-1235.
9. Dong PP, Fang ZZ, Zhang YY, Ge GB, Mao YX, Zhu LL, Qu YQ, Li W, Wang LM, and Liu CX, et al. (2011) Substrate-dependent modulation of the catalytic activity of CYP3A by erlotinib. Acta Pharmacol Sin 32:399-407.
10. Eagling VA, Back DJ, and Barry MG (1997) Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol 44:190-194. (Pubitemid 27327076)
11. Gao B, Yeap S, Clements A, Balakrishnar B, Wong M, and Gurney H (2012) Evidence for therapeutic drug monitoring of targeted anticancer therapies. J Clin Oncol 30:4017-4025.
12. Gramignoli R, Green ML, Tahan V, Dorko K, Skvorak KJ, Marongiu F, Zao W, Venkataramanan R, Ellis EC, and Geller D, et al. (2012) Development and application of purified tissue dissociation enzyme mixtures for human hepatocyte isolation. Cell Transplant 21:1245-1260.
13. Hughes AN, O' Brien ME, Petty WJ, Chick JB, Rankin E, Woll PJ, Dunlop D, Nicolson M, Boinpally R, Wolf J et al. (2009) Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers. J Clin Oncol 27:1220-1226.
14. Katzenmaier S, Markert C, Riedel KD, Burhenne J, Haefeli WE, and Mikus G (2011) Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using A limited sampling strategy. Clin Pharmacol Ther 90:666-673.
15. Kelley RK and Ko AH (2008) Erlotinib in the treatment of advanced pancreatic cancer. Biologics 2:83-95.
16. Kilford PJ, Stringer R, Sohal B, Houston JB, and Galetin A (2009) Prediction of drug clearance by glucuronidation from in vitro data: use of combined cytochrome P450 and UDP-glucuronosyltransferase cofactors in alamethicin-activated human liver microsomes. Drug Metab Dispos 37:82-89.
17. Kobayashi T, Koizumi T, Agatsuma T, Yasuo M, Tsushima K, Kubo K, Eda S, Kuraishi H, Koyama S, and Hachiya T, et al. (2012) A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 69:1241-1246.
18. Komoroski BJ, Zhang S, Cai H, Hutzler JM, Frye R, Tracy TS, Strom SC, Lehmann T, Ang CY, and Cui YY, et al. (2004) Induction and inhibition of cytochromes P450 by the St. John's wort constituent hyperforin in human hepatocyte cultures. Drug Metab Dispos 32:512-518. (Pubitemid 38535029)
19. Kozawa M, Honma M, and Suzuki H (2009) Quantitative prediction of in vivo profiles of CYP3A4 induction in humans from in vitro results with a reporter gene assay. Drug Metab Dispos 37:1234-1241.
20. Li AP and Jurima-Romet M (1997) Applications of primary human hepatocytes in the evaluation of pharmacokinetic drug-drug interactions: evaluation of model drugs terfenadine and rifampin. Cell Biol Toxicol 13:365-374. (Pubitemid 27373407)
21. Li J, Zhao M, He P, Hidalgo M, and Baker SD (2007) Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res 13:3731-3737. (Pubitemid 46955138)
22. Lin JH and Lu AY (2001) Interindividual variability in inhibition and induction of cytochrome P450 enzymes. Annu Rev Pharmacol Toxicol 41:535-567. (Pubitemid 32385898)
23. Ling J, Johnson KA, Miao Z, Rakhit A, Pantze MP, Hamilton M, Lum BL, and Prakash C (2006) Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteers. Drug Metab Dispos 34:420-426. (Pubitemid 43290900)
24. Lodish H, Berk A, Zipursky S, Matsudaira P, Baltimore D, and Darnell J (2000) Molecular Cell Biology, WH Freeman and Company, New York.
25. Lu C, Li P, Gallegos R, Uttamsingh V, Xia CQ, Miwa GT, Balani SK, and Gan LS (2006) Comparison of intrinsic clearance in liver microsomes and hepatocytes from rats and humans: evaluation of free fraction and uptake in hepatocytes. Drug Metab Dispos 34:1600-1605. (Pubitemid 44285402)
26. Lu C, Miwa GT, Prakash SR, Gan LS, and Balani SK (2007) A novel model for the prediction of drug-drug interactions in humans based on in vitro cytochrome p450 phenotypic data. Drug Metab Dispos 35:79-85. (Pubitemid 46043232)
27. Makinson A, Pujol JL, Le Moing V, Peyriere H, and Reynes J (2010) Interactions between cytotoxic chemotherapy and antiretroviral treatment in human immunodeficiency virus-infected patients with lung cancer. J Thorac Oncol 5:562-571.
28. Malfitano A, Barbaro G, Perretti A, and Barbarini G (2012) Human immunodeficiency virus-associated malignancies: a therapeutic update. Curr HIV Res 10:123-132.
29. Messersmith WA, Laheru DA, Senzer NN, Donehower RC, Grouleff P, Rogers T, Kelley SK, Ramies DA, Lum BL, and Hidalgo M (2004) Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities. Clin Cancer Res 10:6522-6527. (Pubitemid 39346546)
30. Messersmith WA, Jimeno A, Jacene H, Zhao M, Kulesza P, Laheru DA, Kahn Y, Spira A, Dancey J, and Iacobuzio-Donahue C, et al. (2010) Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer. Clin Colorectal Cancer 9:297-304.
31. Miller AA, Murry DJ, Owzar K, Hollis DR, Lewis LD, Kindler HL, Marshall JL, Villalona-Calero MA, Edelman MJ, Hohl RJ et al. (2007) Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101. J Clin Oncol 25:3055-3060. (Pubitemid 47218052)
32. Minematsu T and Giacomini KM (2011) Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteins. Mol Cancer Ther 10:531-539.
33. Padda SK, Krupitskaya Y, Chhatwani L, Fisher GA, Colevas AD, San Pedro-Salcedo M, Decker R, Latz JE, and Wakelee HA (2012) A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors. Cancer Chemother Pharmacol 69:1013-1020.
34. Piscitelli SC and Gallicano KD (2001) Interactions among drugs for HIV and opportunistic infections. N Engl J Med 344:984-996. (Pubitemid 32240318)
35. Rakhit A, Pantze MP, Fettner S, Jones HM, Charoin JE, Riek M, Lum BL, and Hamilton M (2008) The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP) predicts in vivo metabolic inhibition. Eur J Clin Pharmacol 64:31-41.
36. Ranson M, Shaw H, Wolf J, Hamilton M, McCarthy S, Dean E, Reid A, and Judson I (2010) A phase I dose-escalation and bioavailability study of oral and intravenous formulations of erlotinib (Tarceva, OSI-774) in patients with advanced solid tumors of epithelial origin. Cancer Chemother Pharmacol 66:53-58.
37. Ricciardi S, Tomao S, and de Marinis F (2009) Toxicity of targeted therapy in non-small-cell lung cancer management. Clin Lung Cancer 10:28-35.
38. Riley RJ, McGinnity DF, and Austin RP (2005) A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes. Drug Metab Dispos 33:1304-1311. (Pubitemid 41196973)
39. Ring BJ, Chien JY, Adkison KK, Jones HM, Rowland M, Jones RD, Yates JW, Ku MS, Gibson CR, and He H, et al. (2011) PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: Comparative assessement of prediction methods of human clearance. J Pharm Sci DOI:10.1002/jps.22552 [published ahead of print].
40. Rudek MA, Flexner C, and Ambinder RF (2011) Use of antineoplastic agents in patients with cancer who have HIV/AIDS. Lancet Oncol 12:905-912.
41. Rudin CM, Liu W, Desai A, Karrison T, Jiang X, Janisch L, Das S, Ramirez J, Poonkuzhali B, Schuetz E et al. (2008) Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol 26:1119-1127.
42. Runge D, Köhler C, Kostrubsky VE, Jäger D, Lehmann T, Runge DM, May U, Stolz DB, Strom SC, and Fleig WE, et al. (2000) Induction of cytochrome P450 (CYP)1A1, CYP1A2, and CYP3A4 but not of CYP2C9, CYP2C19, multidrug resistance (MDR-1) and multidrug resistance associated protein (MRP-1) by prototypical inducers in human hepatocytes. Biochem Biophys Res Commun 273:333-341. (Pubitemid 30426907)
43. Senderowicz AM, Johnson JR, Sridhara R, Zimmerman P, Justice R, and Pazdur R (2007) Erlotinib/gemcitabine for first-line treatment of locally advanced or metastatic adenocarcinoma of the pancreas. Oncology (Williston Park) 21:1696-1706; discussion 1706-1699, 1712, 1715.
44. Sevrioukova IF and Poulos TL (2010) Structure and mechanism of the complex between cytochrome P4503A4 and ritonavir. Proc Natl Acad Sci USA 107:18422-18427.
45. Shiels MS, Pfeiffer RM, Gail MH, Hall HI, Li J, Chaturvedi AK, Bhatia K, Uldrick TS, Yarchoan R, and Goedert JJ, et al. (2011) Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst 103:753-762.
46. Smith PF, DiCenzo R, and Morse GD (2001) Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors. Clin Pharmacokinet 40:893-905. (Pubitemid 34066687)
47. van Erp NP, Gelderblom H, and Guchelaar HJ (2009) Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev 35:692-706.
48. Witherow LE and Houston JB (1999) Sigmoidal kinetics of CYP3A substrates: an approach for scaling dextromethorphan metabolism in hepatic microsomes and isolated hepatocytes to predict in vivo clearance in rat. J Pharmacol Exp Ther 290:58-65. (Pubitemid 29302304)
49. Xu C and Desta Z (2013) In vitro Analysis and Quantitative Prediction of Efavirenz Inhibition of Eight Cytochrome P450 (CYP) Enzymes: Major Effects on CYPs 2B6, 2C8, 2C9 and 2C19. Drug Metab Pharmacokinet PMID: 23385314 [published ahead of print].
50. Yamamoto N, Horiike A, Fujisaka Y, Murakami H, Shimoyama T, Yamada Y, and Tamura T (2008) Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors. Cancer Chemother Pharmacol 61:489-496. (Pubitemid 350275984)
51. Yamamoto T, Itoga H, Kohno Y, Nagata K, and Yamazoe Y (2005) Prediction of oral clearance from in vitro metabolic data using recombinant CYPs: comparison among well-stirred, paralleltube, distributed and dispersion models. Xenobiotica 35:627-646. (Pubitemid 41242918)
52. Yoshida T, Yamada K, Azuma K, Kawahara A, Abe H, Hattori S, Yamashita F, Zaizen Y, Kage M, and Hoshino T (2013) Comparison of adverse events and efficacy between gefitinib and erlotinib in patients with non-small-cell lung cancer: a retrospective analysis. Med Oncol 30:349.
53. Zhou S, Yung Chan S, Cher Goh B, Chan E, Duan W, Huang M, and McLeod HL (2005) Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet 44:279-304. (Pubitemid 40477790)